taiga biotechnologies on radar

Taiga Biotechnologies: On the Radar

I am excited to learn about Taiga Biotechnologies now residing at the

Colorado Science + Technology Park @ Fitzsimons. Though no news to

report this is an effort to break down what they have and what they

are doing.

Taiga was founded to develop novel approaches for the treatment

hematological diseases; including cancers, immunodeficiencies and

autoimmune conditions, a triangulated approach. Their model combines

novel breakthroughs in cellular, biologic and small molecule

approaches to treat and manage these diseases.

Picks. Shovels. And products. The Taiga platform enables screens for

small molecule discovery and validation. Three small molecule

candidates are in their pipeline for acute myelogenous Leukemia and

are moving towards IND enabling studies. The proprietary screening

platform allows Taiga to perform differential screens to identify

novel agents that will specifically kill leukemic stem cells, but

spare normal blood stem cells.

Stem cell therapeutics. Taiga continues to develop and test their

long-term hematopoietic stem cells which have demonstrated efficacy in

the treatment of a variety of cancers in animal models. Poised to

transition to the clinic, the lead indications for this program

include acute lymphoblastic leukemia, acute myeloid leukemia, and

chronic myeloid leukemia.

And biologics too. Taiga has also developed an innovative method for

rapidly generating monoclonal antibodies for treating cancer and

infectious disease. What is unique here is that Tiaga's monoclonal

Antibodies can be generated 3-4X faster than current production

technologies. Development of fully humanized antibodies for the

treatment of disease has become a primary focus of Taiga, though

uncertain as to the status of this program.

I encourage the founders Brian Turner, Ph.D., Yosef Refaeli, Ph.D. and

John Cambier, Ph.D. from the University Colorado Health Science Center

and the National Jewish Medical Research Center to right the ship if

the post missed the mark be either leaving a comment and/or shooting

me an email, arubenstein [at] rnaventures [dot] com.

***Update*** Be sure to get your vote in for the CLSDF Readers Company

of the Year Award. GlobeImmune continues to add to its commanding

lead. Voting ends on 31 January.

If you enjoyed this post get free email or RSS updates (here).